Phase I Dose Escalation Study of Bortezomib in Combination with Lenalidomide in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

We conducted a phase I dose escalation study to determine the maximal tolerated dose of bortezomib that could be combined with standard dose lenalidomide in patients with MDS or AML. Treatment consisted of bortezomib (IV) on Days 1, 4, 8, and 11 and lenalidomide 10 mg daily (PO) days 1–21 in 28 day...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Attar, Eyal C., Amrein, Philip C., Fraser, James W., Fathi, Amir, McAfee, Steven, Wadleigh, Martha, DeAngleo, Daniel J., Steensma, David, Stone, Richard M., Foster, Julia, Neuberg, Donna, Ballen, Karen K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3969839/
https://ncbi.nlm.nih.gov/pubmed/23773898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2013.05.011
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi